Industry
Medical - Diagnostics & Research
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Loading...
Open
32.39
Mkt cap
3.5B
Volume
5.3M
High
33.64
P/E Ratio
-6.96
52-wk high
37.04
Low
28.24
Div yield
N/A
52-wk low
15.81
Portfolio Pulse from Avi Kapoor
September 16, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 5:41 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 12:13 pm
Portfolio Pulse from Avi Kapoor
August 26, 2024 | 12:25 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 1:51 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 3:21 pm
Portfolio Pulse from Benzinga Neuro
August 09, 2024 | 2:39 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 7:23 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 6:06 pm
Portfolio Pulse from Benzinga Insights
August 08, 2024 | 6:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.